On 26 March 2013, Xeltis was honoured with the esteemed ‘Next Gem Award in Medtech‘ from Biovision.
The illustrious Selection Committee, awarding Xeltis the prize, represents nearly € 10 billion under management, is chaired by Roman Fleck, Index Ventures and is coordinated by Jean-Marc Soustre, Humaneye Invest. From initially 280 company evaluations, down to 150 preselections, 37 companies were finally invited to present at the Biovision Investor Conference in Lyon, France.
‘This prize is a clear and independent recognition of the quality of the work Xeltis is conducting and the incredibly game-changing impact our technology can have on current clinical practice. The whole Xeltis team and I are excited and honoured to have received this prestigious Award’, said Laurent Grandidier, Xeltis CEO.
Biovision, the World Life Sciences Forum, was held between 24-26 March 2013. BIOVISION brings together top decision-makers from the academic, private, policy-making and civil society sectors to translate innovative ideas into actionable solutions for the benefit of citizens. There were more than 3,000 participants from 60 different countries, and 100 media representatives at the conference.
Click here for more details.
